EligibleTrials

Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation

Recruiting · NCT06853886 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Limoges

View the official record on ClinicalTrials.gov →
Hepatitis B

Interventions studied

blood sample HBV patientblood sample healthy volunteers

What this trial is about

Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

3 locations listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.